Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.

Ahmed R. et al, (2023), Cancers, 15

Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.

Lucca I. et al, (2022), European urology open science, 45, 55 - 58

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.

Nguyen S. et al, (2022), Journal for immunotherapy of cancer, 10

Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.

Benmerzoug S. et al, (2022), European urology focus, 8, 748 - 751

Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.

Benmerzoug S. et al, (2021), European urology open science, 34, 79 - 82

Fibroblast-derived IL-33 is dispensable for lymph node homeostasis but critical for CD8 T-cell responses to acute and chronic viral infection.

Aparicio-Domingo P. et al, (2021), European journal of immunology, 51, 76 - 90

Include forthcoming?

In this section